MORL Screening Methodology

Enzyme linked immunosorbent assay (ELISA).

  • 1ml frozen serum 

Click here to print sample and shipping requirements.

  • Serum samples must be frozen to below -80°C immediately after separation from cells and shipped on dry ice. These samples remain viable for at least six months when stored at -80°C.

  • All serum samples MUST be processed and frozen down to -80°C immediately after collection
  • Labeled with the sample type AND patient’s name, DOB, MRN and sex
  • Cryovials should be put in zip lock bags and completely covered in dry ice to keep the sample frozen until it arrives in the lab
  • Shipped overnight on at least 5 lbs of dry ice
  • Shipping and receiving dock closed on weekends and holidays 
    • Deliveries accepted Monday - Friday 

If samples arrive thawed they will be REJECTED.

 

Click here to print sample and shipping requirements.

Dense Deposit Disease (DDD, aka Membranoproliferativee Glomerulonephritis Type II, MPGNII)
C3 Glomerulonephritis (C3GN)
Atypical Hemolytic Uremic Syndrome (aHUS)
Factor B autoantibodies (FBAAs) have been associated with DDD (Strobel, et al. 2010; Chen, et al. 2011). FBAA binds to factor B and/or the individual component Bb part of C3 convertase. More importantly, FBAA enhances C3 convertase activity, which often leads to increased complement breakdown products. FBAA represents an additional acquired driver of disease in DDD, C3GN and aHUS. Although rare, FBAAs should be considered in the comprehensive evaluation of patients with DDD, C3GN and aHUS.

Information

Quick Facts

  • CPT code: 83516
  • Test code: 07FBAA
  • Turnaround time: 2 weeks
  • Cost: $356
Requisition Form

To order:

Use this requisition form to order this test.

Background

Factor B autoantibodies (FBAAs) are antibodies that specifically target factor B and/or its cleavage product, Bb.  By binding to either factor B or Bb, FBAAs can augment the activity of C3 convertase, leading to heightened production of complement activation products.  

FBAAs are recognized as an additional acquired contributor to disease pathology in conditions such as post-infectious glomerulonephritis, C3 glomerulopathy, and atypical hemolytic uremic syndrome/complement-mediated TMA. Notably, however, recent research has shed light on the prevalence of FBAAs, particularly their association with post-infectious glomerulonephritis (Chauvet et al., 2020). 

The Clinical Diagnostics Service of the Molecular Otolaryngology & Renal Research Laboratories is a CLIA-approved, Joint Commission-accredited diagnostic laboratory.